

# **Galactosylation of IgA1 is associated with common variation in *C1GALT1***

Daniel P Gale<sup>1</sup>, Karen Molyneux<sup>2</sup>, David Wimbury<sup>2</sup>, Patricia Higgins<sup>2</sup>, Adam P Levine<sup>3</sup>, Ben Caplin<sup>1</sup>, Anna Ferlin<sup>1</sup>, Peiran Yin<sup>4</sup>, Christopher P Nelson<sup>5</sup>, Horia Stanescu<sup>1</sup>, Nilesh J Samani<sup>5</sup>, Robert Kleta<sup>1</sup>, Xueqing Yu<sup>4</sup>, Jonathan Barratt<sup>2</sup>

<sup>1</sup>Centre for Nephrology, University College London, UK

<sup>2</sup>Department of Infection, Immunity & Inflammation, University of Leicester, UK

<sup>3</sup>Division of Medicine, University College London, UK

<sup>4</sup>Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

<sup>5</sup>Department of Cardiovascular Sciences, University of Leicester & National Institute for Health Research Leicester Cardiovascular Biomedical Research Unit, Leicester, UK

Running title: C1GALT1 and IgA

Abstract: 241 words

Text: 2475 words

Daniel Gale, UCL Centre for Nephrology, Royal Free Hospital, London NW3 2QG, UK.

Email: [d.gale@ucl.ac.uk](mailto:d.gale@ucl.ac.uk)

Tel: +44 (0)207 7940500; Fax: +44 (0)207 3178591

## Abstract

IgA nephropathy (IgAN), an important cause of kidney failure, is characterized by glomerular IgA deposition and is associated with changes in *O*-glycosylation of the IgA1 molecule. Here, we sought to identify genetic factors contributing to levels of galactose-deficient IgA1 (Gd-IgA1) in Caucasian and Chinese populations.

Gd-IgA1 levels were elevated in IgAN patients compared with ethnically matched healthy subjects and correlated with evidence of disease progression. Caucasian IgAN patients exhibited significantly higher Gd-IgA1 levels than Chinese patients. Among individuals without IgAN, Gd-IgA1 levels were not correlated with kidney function. Gd-IgA1 level heritability ( $h^2$ ), estimated by comparing mid-parental and offspring Gd-IgA1 levels, was 0.39. Linear regression genome wide association study (GWAS) identified alleles at a single locus spanning the *C1GALT1* gene that was strongly associated with Gd-IgA1 level (Beta = 0.26;  $p = 2.35 \times 10^{-9}$ ). This association was replicated in GWAS of separate cohorts comprising: 308 UK patients with membranous glomerulonephritis ( $p < 10^{-6}$ ); 622 UK controls with normal kidney function ( $p < 10^{-10}$ ); and in a candidate gene study 704 Chinese patients with IgAN ( $p < 10^{-5}$ ). The same extended haplotype was associated with elevated Gd-IgA1 levels in all cohorts studied.

*C1GALT1* encodes a galactosyltransferase enzyme known to be important in *O*-galactosylation of glycoproteins. These findings demonstrate that common variation at *C1GALT1* influences Gd-IgA1 level in the population, which is independently associated with risk of progressive IgAN, and that the pathogenic importance of changes in IgA1 *O*-glycosylation may vary between Caucasian and Chinese patients with IgAN.

## Introduction

IgA nephropathy (IgAN) is the commonest glomerulonephritis worldwide and is a major cause of kidney failure<sup>1</sup>. The prevalence of IgAN shows marked differences across different ethnic groups, being more prevalent in people with East Asian ancestry and less prevalent in people with African ancestry compared with Caucasians<sup>2</sup>. In addition, differences in the clinical features of IgAN in Caucasian compared with Chinese patients have been recognized for a long time<sup>3</sup>, most notably the clear male preponderance of IgAN in Caucasian studies of IgAN that is absent (or even reversed) in East Asian populations, suggesting that important and incompletely understood differences in disease pathophysiology exist across different populations<sup>4-8</sup>. Recent work has identified a number of genetic factors, mostly associated with mechanisms of defense against infection, that are associated with altered risk of disease<sup>9-11</sup>, and although the prevalence of the known genetic factors vary across different ethnic groups, the observed differences fall some way short of explaining the differences in prevalence of the disease in different regions<sup>2, 12</sup>.

The human IgA1 molecule differs from the conserved IgA2 sub-class by the presence of an additional 13-residue motif in the hinge region that undergoes *O*-linked glycosylation. The function of this post-translational modification is incompletely understood, but it is known that IgA1 *O*-linked glycans lacking a galactose moiety are more abundant in the circulation of patients with IgAN<sup>13-15</sup>, and that such galactose deficient IgA1 (Gd-IgA1) is disproportionately found in IgAN glomerular immune deposits<sup>16</sup>. In Tn syndrome, a similarly undergalactosylated protein is present on the surfaces of blood cells that leads to autoantibody generation and disease<sup>17</sup>. A plausible hypothesis is that Gd-IgA1 plays an important role in the pathophysiology of IgAN by functioning as an autoantigen leading to autoantibody production and formation of circulating immune complexes in susceptible individuals<sup>18, 19</sup>. *In vitro* evidence supports a role for these IgA-containing immune complexes in driving glomerular injury through mesangial cell proliferation and secretion of cytokines, chemokines, growth factors and extracellular matrix components promoting glomerular inflammation and glomerulosclerosis<sup>20-22</sup>. Consistent with previous data, we show that Gd-IgA1 level

is a heritable trait<sup>23-26</sup> and use a genome-wide approach to identify the common genetic factor that influences Gd-IgA1 levels in Caucasian and East Asian populations.

## Results

**Gd-IgA1 is elevated in IgAN, associated with disease severity and heritable.** In the discovery UK cohort, Gd-IgA1 levels were normally distributed (Supplementary Figure S1) and elevated in patients. Follow-up data were available for the majority of patients allowing classification into 154 'progressors', defined as doubling of serum creatinine or needing renal replacement therapy, and 123 'non-progressors', defined as serum creatinine below 1.35 mg/dL and less than 20% increase over at least 5 years of follow-up, with the remainder 'indeterminate'. Gd-IgA1 levels were significantly higher in progressors compared with non-progressors ( $p = 0.0011$ ; Figure 1). Correlation ( $p = 0.031$ ) was seen between Gd-IgA1 level and serum creatinine<sup>-1</sup> (Supplementary Figure S2). In a separate longitudinal cohort of IgAN patients and healthy subjects (Leicester Research Archive) we observed that the Gd-IgA1 level in an individual did not change significantly over >5 years and changes in renal function in individuals with IgAN were not correlated with changes in Gd-IgA1 level (Supplementary Figure S3). Heritability ( $h^2$ ) was 0.387, estimated by parent-off-spring regression of standardized Gd-IgA1 levels (Figure 2), broadly consistent with previously published data<sup>23-26</sup>.

**C1GALT1 is principal genetic determinant of Gd-IgA1 level in multiple cohorts.** Linear regression genome wide association study (GWAS) using standardized Gd-IgA1 levels in 513 founder members of the discovery cohort identified alleles at a single locus, spanning the *C1GALT1* gene, that was strongly associated with Gd-IgA level (Beta = 0.26;  $p=2.35 \times 10^{-9}$ ), with no other significantly associated alleles elsewhere in the genome (Figure 3 and Table 1). Repeating the analysis conditioned on the most strongly associated SNP (rs1008897), showed no association with any independent alleles, either at *C1GALT1* or elsewhere in the genome (Supplementary Figure S4). The association with *C1GALT1* was robust to correction for age, sex, renal function and progression, and genomic inflation factor ( $\lambda$ ) was 1.00196 suggesting the analysis was unlikely to be confounded by unidentified population substructure. Haplotype analyses confirmed the findings of the conditional analysis, which was that the association was attributable to the presence of a single haplotype, termed H1, present at a frequency of >0.3 in the UK population and strongly associated with

increased Gd-IgA1 levels (Beta = 0.34;  $p = 4.4 \times 10^{-11}$ ; Table 2 and Supplementary Figure S5).

Additional haplotype association analysis conditioned on the presence of H1 indicated that no other haplotypes were significantly associated with Gd-IgA1 at either the genome-wide or nominal level corrected for multiple tests (Supplementary Table 1).

In a cohort of 318 UK Caucasian patients with biopsy-proven membranous nephropathy (MN), sera for Gd-IgA1 measurements were available for 308 and values were lower than IgAN patients and similar to values in healthy subjects (Figure 1). Among the MN cohort, >30% of subjects had eGFR <60 ml/min but, unlike in patients with IgAN, we observed no correlation between Gd-IgA1 levels and serum creatinine<sup>-1</sup> (Supplementary Figure S2). Genome-wide linear regression analysis of Gd-IgA1 levels within the MN cohort revealed association between Gd-IgA1 and the same alleles as observed in the discovery cohort (Supplementary Figure S6). In the combined analysis of 821 individuals no associations at or approaching genome-wide significance (defined as  $p < 5 \times 10^{-8}$ ) at other loci were detected. Intriguingly, weak evidence of association ( $p \sim 10^{-5}$ ) was seen at the X-chromosomal *C1GALT1C1* locus encoding Cosmc (Supplementary Figure S7), which is necessary for the *C1GALT1* gene product to function.

Among 622 participants in the UK GRAPHIC cohort (who all lacked evidence of renal impairment), strong association was again observed with alleles at the *C1GALT1* locus (Beta = 0.38,  $p < 3.6 \times 10^{-11}$ , Supplementary Figure S8), with no other loci implicated. Univariate and multivariate analyses demonstrated no significant association with age, sex, or other baseline characteristics including creatinine clearance and eGFR (Beta < 0.001 and  $p > 0.5$  for both). This therefore replicates the association of the H1 haplotype with elevated Gd-IgA1 in Caucasians, and implies that differences in renal function *per se* do not influence Gd-IgA1 level.

**The same *C1GALT1* haplotype is rare but also associated with Gd-IgA1 in the Chinese population.** Data from the HapMap project indicate that, although common in Europeans, the H1 haplotype is less common in African and East Asian populations<sup>27</sup>. To investigate how genetic

variation across this locus influences Gd-IgA1 levels in a Chinese population we measured serum Gd-IgA1 levels in a cohort of 704 Chinese patients (51% male) with IgAN, and 111 ethnicity and age-matched controls. This demonstrated that Gd-IgA1 levels were significantly higher in Chinese patients than Chinese healthy subjects, but in both these groups Gd-IgA1 levels were lower than UK subjects (Figure 4).

We next performed a candidate locus association study by genotyping 38 SNPs across the *C1GALT1* locus and observed association of alleles at this locus with Gd-IgA1 level ( $p = 5 \times 10^{-4}$ ; Supplementary Figure S9). Consistent with HapMap data, we observed that the H1 haplotype was present but rare in this population, with a frequency of 0.035. The presence of this haplotype was again associated with elevated Gd-IgA1 levels (Table 2,  $p = 6 \times 10^{-5}$ ). Multiple regression analyses showed that disease status, ethnicity and the presence of the H1 haplotype were all independently correlated with Gd-IgA1 level, but age and sex were not: Gd-IgA1 levels remained significantly higher in Caucasian compared with Chinese subjects when stratified by number of copies of the H1 haplotype (Figure 5;  $p < 10^{-8}$ ).

## Discussion

Elevation of serum Gd-IgA1 is a consistent finding in IgAN that, in susceptible individuals, is associated with autoantibody production and the formation of circulating immune complexes that trigger glomerular injury through mesangial cell activation, endocapillary proliferation, podocyte injury and tubulointerstitial inflammation and fibrosis<sup>16, 18, 20-22</sup>. Delineating the genetic control of Gd-IgA1 production is therefore important in understanding this common glomerulonephritis.

In Caucasian and Chinese populations we identified association between Gd-IgA1 levels and a haplotype spanning the *C1GALT1* gene. *C1GALT1* encodes the enzyme Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase (C1GALT1), which catalyzes the transfer of Galactose (Gal) from UDP-Gal to N-acetylgalactosamine (GalNAc) *O*-linked esters of Threonine and Serine residues of target proteins, including IgA1, to form the T antigen. This requires the chaperone Cosmc, encoded by the X-linked gene *C1GALT1C1*, which prevents rapid degradation of C1GALT1<sup>28</sup>. We also observed possible association between Gd-IgA1 and variation at *C1GALT1C1*, although this was not statistically significant at the genome-wide level. Mice lacking C1GALT1 develop thrombocytopenia, proteinuria and renal failure associated with anomalous glycosylation of proteins<sup>29</sup>. Somatic mutations inactivating Cosmc (leading to increased degradation of C1GALT1) cause Tn syndrome in humans, which is characterized by autoantibodies forming against the undergalactosylated *O*-linked glycoproteins on red cell membranes.<sup>17</sup> It therefore appears likely that variation at *C1GALT1* might similarly modulate galactosylation of *O*-glycosylated proteins, including IgA1, resulting in generation of IgA1 neo-epitopes capable of triggering autoantibody production and disease in susceptible individuals.

There is, however, no evidence for a generalised defect in *O*-galactosylation in IgAN: we have previously shown that in IgAN the patterns of *O*-galactosylation of C1 inhibitor and IgD, the only other *O*-glycosylated human immunoglobulin isotype, are unaltered, implying that the reduction in IgA1 *O*-galactosylation in IgAN is a specific feature of IgA1-secreting cells<sup>30</sup>. This suggests that the

haplotype we identified leads to elevated Gd-IgA1 through altered maturation-dependent transcriptional regulation of *C1GALT1*, rather than via differences in C1GALT1 protein structure that would be present in all C1GALT1-expressing cell types. Consistent with this, imputation of all the alleles common to the H1 haplotype using 1000 Genomes data identified no coding variants in linkage disequilibrium with the associated alleles. Furthermore, published data linking genetic variation with gene expression (eQTLs) in lymphoblastoid cell lines show that SNP alleles imputed to lie on the H1 haplotype are strongly associated with reduced *C1GALT1* transcript levels (Table 3)<sup>31</sup>. Additional *in silico* analyses using ENCODE data show that some strongly associated SNPs lie within consensus transcription factor binding elements, including rs7780273 (imputed  $p = 1.8 \times 10^{-8}$ ; eQTL  $p$ -value of  $7.5 \times 10^{-7}$ ), which lies at a predicted SOX2-OCT4 site<sup>32, 33</sup> and rs758263, which lies within the core promoter region for *C1GALT1* and is predicted to affect binding of RUNX3, a transcription factor present in B cells that is necessary for class switching to IgA production<sup>34, 35</sup>. These *in silico* predictions coupled with previous *in vitro* data demonstrating modulation of IgA1 O-galactosylation by Th2 cytokines and IL-6<sup>36, 37</sup>, as well as our previous observation that IgA1 O-galactosylation varies depending on the site of antigen encounter and B cell activation<sup>38</sup>, are consistent with an effect of the H1 haplotype on transcriptional control of *C1GALT1* particularly in IgA1-committed B cells.

Our data indicate that *C1GALT1* genotype explains ~3% of the variability in Gd-IgA1 levels, suggesting other factors are important in determining Gd-IgA1 levels in an individual. Because this is a genome-wide study it is unlikely that variation at any other single locus is responsible for this, and we also exclude the possibility that kidney function itself significantly affects Gd-IgA1 levels. Cytokines, and presumably other stimuli, acting in B cells can influence IgA1 galactosylation<sup>37</sup>, and likely contribute to the variability in Gd-IgA1 levels. Identification of the transcriptional mechanisms influencing *C1GALT1* expression may provide insights into how Gd-IgA1 levels are controlled in health and disease.

Association between *C1GALT1* and IgAN susceptibility has previously been tested in candidate gene studies: Li et al<sup>39,40</sup> genotyped 9 SNPs in Asian cohorts and reconstructed haplotypes across the gene. They identified evidence of association between the disease and the presence of haplotypes containing rs1047763(G) allele (designated “YATDG” and “ATDG”). Although this allele was also associated with the disease in an Italian study<sup>41</sup>, these associations with disease risk have not been replicated in larger genome-wide studies.<sup>9-11,42,43</sup> We found that rs1047763(G) was associated with Gd-IgA1 level in both our discovery ( $p = 8.7 \times 10^{-6}$ ) and replication ( $p = 2 \times 10^{-6}$ ) cohorts, and is present on the H1 haplotype, consistent with increased disease susceptibility being mediated by increased Gd-IgA1 levels.

A limitation of this and other GWASs in IgAN is the lack of clear evidence of association with IgAN susceptibility at this locus. Our data show that for each standard deviation increase in Gd-IgA1, the odds of IgAN increased by a ratio of 1.52 (95% confidence interval 1.35 to 1.73), and in the Caucasian discovery cohort the  $R^2$  value associating the H1 haplotype with Gd-IgA1 level was 0.033 (implying that 3.3% of the variation in Gd-IgA1 level is explained by the number of copies of H1 haplotype). Power calculation, performed as described previously<sup>44</sup>, indicates that a candidate gene study (with nominal  $\alpha$  0.05) in the Caucasian population would need over 5300 participants to have >80% power to detect an effect of the H1 haplotype on risk of IgAN. In a GWAS (where  $\alpha$  is typically  $< 5 \times 10^{-8}$ ) a study around 5 times larger would be needed. In Chinese subjects the H1 haplotype is less common, and we observed an  $R^2$  of 0.019, implying that previously published studies in this population have been underpowered to detect an association with disease risk: even the largest published meta-GWAS study, comprising 7,600 cases and 13,000 controls<sup>45</sup> has <10% power to detect an association between *C1GALT1* and disease.

Perhaps the most surprising finding in this study was the disparity in levels of Gd-IgA1 between Caucasian and Chinese subjects, both healthy and with IgAN. All Gd-IgA1 level measurements were performed in the same laboratory using the same batch of HA-lectin across all samples, with the

same standards run in all plates, allowing direct comparison of Gd-IgA1 levels across the different cohorts. This is the first time such a comparison has been reported and indicates that the increased prevalence of IgAN in China cannot be attributed to differences in Gd-IgA1 levels. This, together with the differences in frequency of the H1 haplotype and the clinical manifestations of IgAN described in different continents, suggests that different pathogenic pathways may be operating in different populations. Previous studies have shown that IgAN susceptibility is associated with variation at genes involved in immune defense and higher-risk alleles are more prevalent in East Asians<sup>2, 12</sup>. One possibility is that the high burden of immunological risk alleles in East Asian populations results in a higher likelihood of a damaging immunological response to Gd-IgA1 in the circulation, and hence a higher likelihood of kidney disease. In this paradigm, the reduced Gd-IgA1 in Chinese subjects might even have resulted from selection against the H1 haplotype in this population due to the high prevalence of other risk alleles that increase disease susceptibility.

In summary, we demonstrate that circulating Gd-IgA1 levels are heritable and influenced by genetic variation at the *C1GALT1* gene across different populations. This provides the first direct evidence that common genetic variation can influence *O*-glycosylation in humans. Our observations suggest that modulation of this pathway might influence susceptibility to, or outcomes in, IgAN and *C1GALT1* activity would be the logical enzymatic step to target in order to test this hypothesis.

## Concise Methods

Discovery cohort: UK Glomerulonephritis DNA Bank (UKGDB) from individuals with biopsy-proven IgA nephropathy (66% male) and healthy relatives has been previously described<sup>11</sup>. After quality control for ethnicity (using principal component analysis), genotyping rate and excluding cryptic relatedness, estimated from identity-by-state information ( $\hat{\pi} > 0.125$ ), serum and genotype data were available for 379 UK Caucasian patients and 309 of their parents in 134 parent-affected trios. All individuals were genotyped at 318,127 SNPs using the Illumina Sentrix HumanHap300 BeadChip, of which 302,210 passed quality control ( $>90\%$  genotyping rate, Minor Allele Frequency  $>0.05$ , Hardy Weinberg Equilibrium  $p > 0.001$ ). Follow-up data allowed 277 of these patients to be classed as 'progressors' (end stage kidney disease or doubling of serum creatinine) or 'non-progressors' (normal renal function and  $<20\%$  rise in serum creatinine over  $>5$  years' follow-up) with the remainder classed as 'indeterminate'.

UK replication cohorts: Replication was performed using serum from 308 Caucasian UK patients with biopsy-proven membranous glomerulopathy from the UKGDB<sup>46</sup> genotyped using the Illumina HumanCNV370-Quad SNP chip. Further independent replication was performed using 622 samples from unrelated adults from the GRAPHIC (Genetic Regulation of Arterial Pressure of Humans in the Community) cohort, in which all individuals had normal urinalysis and plasma urea and creatinine at recruitment<sup>47</sup>.

Chinese replication cohort: DNA and sera were available from 704 Han Chinese patients from the Guangzhou (49% male) with biopsy-proven IgA nephropathy and 111 healthy age- and sex-matched subjects. Gd-IgA1 was measured and each patient was genotyped at 38 SNPs across the *C1GALT1* gene, selected using Haploview<sup>48</sup> to tag  $>90\%$  of haplotypes present in the Chinese population. All subjects provided informed written consent to genetic analyses and the study was performed according to the principles of the Declaration of Helsinki with local ethical approval at each site.

Genome-wide linear regression association analyses were performed with Plink<sup>49, 50</sup> using Gd-IgA1 data standardized to a mean of 0 and a standard deviation of 1 to allow interpretation of Beta, as detailed in supplementary methods. Haplotypes were visualized using Haploview<sup>48</sup>. Genotypes were imputed using the University of Michigan imputation server<sup>51</sup>. ANOVA and linear regression tests were performed using R. Gd-IgA1 levels were measured using a *Helix aspersa* (HA) lectin based ELISA method as previously described (see supplementary material)<sup>52</sup>.

## **Acknowledgements**

This study was supported by a UK National Institute of Health Research Translational Research Collaboration in Rare Disease Grant, The Mayer Family Trust and Kidney Research UK. DPG is supported by the Medical Research Council. CPN and NJS are supported by the British Heart Foundation and NJS is a UK National Institute of Health Research Senior Investigator.

## **Statement of competing financial interests**

None

## References

1. D'Amico, G: The commonest glomerulonephritis in the world: IgA nephropathy. *The Quarterly journal of medicine*, 64: 709-727, 1987.
2. Kiryluk, K, Li, Y, Sanna-Cherchi, S, Rohanizadegan, M, Suzuki, H, Eitner, F, Snyder, HJ, Choi, M, Hou, P, Scolari, F, Izzi, C, Gigante, M, Gesualdo, L, Savoldi, S, Amoroso, A, Cusi, D, Zamboli, P, Julian, BA, Novak, J, Wyatt, RJ, Mucha, K, Perola, M, Kristiansson, K, Viktorin, A, Magnusson, PK, Thorleifsson, G, Thorsteinsdottir, U, Stefansson, K, Boland, A, Metzger, M, Thibaudin, L, Wanner, C, Jager, KJ, Goto, S, Maixnerova, D, Karnib, HH, Nagy, J, Panzer, U, Xie, J, Chen, N, Tesar, V, Narita, I, Berthoux, F, Floege, J, Stengel, B, Zhang, H, Lifton, RP, Gharavi, AG: Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. *PLoS genetics*, 8: e1002765, 2012.
3. Li, L, Tao, K, Nicholls, K, Kincaid-Smith, P: [IgA nephropathy in Chinese and Australian patients: a comparison between clinical and pathological features]. *Zhonghua yi xue za zhi*, 71: 153-155, 112, 1991.
4. Stefan, G, Ismail, G, Stancu, S, Zugravu, A, Andronesi, A, Mandache, E, Mircescu, G: Validation study of Oxford Classification of IgA Nephropathy: the significance of extracapillary hypercellularity and mesangial IgG immunostaining. *Pathology international*, 66: 453-459, 2016.
5. Pesce, F, Diciolla, M, Binetti, G, Naso, D, Ostuni, VC, Di Noia, T, Vagane, AM, Bjornekleit, R, Suzuki, H, Tomino, Y, Di Sciascio, E, Schena, FP: Clinical decision support system for end-stage kidney disease risk estimation in IgA nephropathy patients. *Nephrol Dial Transplant*, 31: 80-86, 2016.
6. Floege, J, Rauen, T, Eitner, F: Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. *N Engl J Med*, 374: 992-993, 2016.
7. Xu, X, Ning, Y, Shang, W, Li, M, Ku, M, Li, Q, Li, Y, Dai, W, Shao, J, Zeng, R, Han, M, He, X, Yao, Y, Lv, Y, Liu, X, Ge, S, Xu, G: Analysis of 4931 renal biopsy data in central China from 1994 to 2014. *Renal failure*, 38: 1021-1030, 2016.
8. Watanabe, H, Goto, S, Kondo, D, Takata, T, Yamazaki, H, Hosojima, M, Yamamoto, S, Kaneko, Y, Aoyagi, R, Narita, I: Comparison of methods of steroid administration combined with tonsillectomy for IgA nephropathy patients. *Clinical and experimental nephrology*, 2016.
9. Yu, XQ, Li, M, Zhang, H, Low, HQ, Wei, X, Wang, JQ, Sun, LD, Sim, KS, Li, Y, Foo, JN, Wang, W, Li, ZJ, Yin, XY, Tang, XQ, Fan, L, Chen, J, Li, RS, Wan, JX, Liu, ZS, Lou, TQ, Zhu, L, Huang, XJ, Zhang, XJ, Liu, ZH, Liu, JJ: A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. *Nat Genet*, 44: 178-182, 2012.
10. Gharavi, AG, Kiryluk, K, Choi, M, Li, Y, Hou, P, Xie, J, Sanna-Cherchi, S, Men, CJ, Julian, BA, Wyatt, RJ, Novak, J, He, JC, Wang, H, Lv, J, Zhu, L, Wang, W, Wang, Z, Yasuno, K, Gunel, M, Mane, S, Umlauf, S, Tikhonova, I, Beerman, I, Savoldi, S, Magistroni, R, Ghiggeri, GM, Bodria, M, Lugani, F, Ravani, P, Ponticelli, C, Allegri, L, Boscutti, G, Frasca, G, Amore, A, Peruzzi, L, Coppo, R, Izzi, C, Viola, BF, Prati, E, Salvadori, M, Mignani, R, Gesualdo, L, Bertinetto, F, Mesiano, P, Amoroso, A, Scolari, F, Chen, N, Zhang, H, Lifton, RP: Genome-wide association study identifies susceptibility loci for IgA nephropathy. *Nat Genet*, 43: 321-327, 2011.
11. Feehally, J, Farrall, M, Boland, A, Gale, DP, Gut, I, Heath, S, Kumar, A, Peden, JF, Maxwell, PH, Morris, DL, Padmanabhan, S, Vyse, TJ, Zawadzka, A, Rees, AJ, Lathrop, M, Ratcliffe, PJ: HLA has strongest association with IgA nephropathy in genome-wide analysis. *J Am Soc Nephrol*, 21: 1791-1797, 2010.
12. Ai, Z, Li, M, Liu, W, Foo, JN, Mansouri, O, Yin, P, Zhou, Q, Tang, X, Dong, X, Feng, S, Xu, R, Zhong, Z, Chen, J, Wan, J, Lou, T, Yu, J, Fan, J, Mao, H, Gale, D, Barratt, J, Armour, JA, Liu, J, Yu, X: Low alpha-defensin gene copy number increases the risk for IgA nephropathy and renal dysfunction. *Science translational medicine*, 8: 345ra388, 2016.

13. Hiki, Y, Tanaka, A, Kokubo, T, Iwase, H, Nishikido, J, Hotta, K, Kobayashi, Y: Analyses of IgA1 hinge glycopeptides in IgA nephropathy by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *J Am Soc Nephrol*, 9: 577-582, 1998.
14. Allen, AC, Bailey, EM, Barratt, J, Buck, KS, Feehally, J: Analysis of IgA1 O-glycans in IgA nephropathy by fluorophore-assisted carbohydrate electrophoresis. *J Am Soc Nephrol*, 10: 1763-1771, 1999.
15. Renfrow, MB, Cooper, HJ, Tomana, M, Kulhavy, R, Hiki, Y, Toma, K, Emmett, MR, Mestecky, J, Marshall, AG, Novak, J: Determination of aberrant O-glycosylation in the IgA1 hinge region by electron capture dissociation fourier transform-ion cyclotron resonance mass spectrometry. *The Journal of biological chemistry*, 280: 19136-19145, 2005.
16. Allen, AC, Bailey, EM, Brenchley, PE, Buck, KS, Barratt, J, Feehally, J: Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. *Kidney Int*, 60: 969-973, 2001.
17. Ju, T, Cummings, RD: Protein glycosylation: chaperone mutation in Tn syndrome. *Nature*, 437: 1252, 2005.
18. Suzuki, H, Fan, R, Zhang, Z, Brown, R, Hall, S, Julian, BA, Chatham, WW, Suzuki, Y, Wyatt, RJ, Moldoveanu, Z, Lee, JY, Robinson, J, Tomana, M, Tomino, Y, Mestecky, J, Novak, J: Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. *J Clin Invest*, 119: 1668-1677, 2009.
19. Huang, ZQ, Raska, M, Stewart, TJ, Reily, C, King, RG, Crossman, DK, Crowley, MR, Hargett, A, Zhang, Z, Suzuki, H, Hall, S, Wyatt, RJ, Julian, BA, Renfrow, MB, Gharavi, AG, Novak, J: Somatic Mutations Modulate Autoantibodies against Galactose-Deficient IgA1 in IgA Nephropathy. *J Am Soc Nephrol*, 2016.
20. Amore, A, Cirina, P, Conti, G, Brusa, P, Peruzzi, L, Coppo, R: Glycosylation of circulating IgA in patients with IgA nephropathy modulates proliferation and apoptosis of mesangial cells. *J Am Soc Nephrol*, 12: 1862-1871, 2001.
21. Novak, J, Vu, HL, Novak, L, Julian, BA, Mestecky, J, Tomana, M: Interactions of human mesangial cells with IgA and IgA-containing immune complexes. *Kidney Int*, 62: 465-475, 2002.
22. Moura, IC, Arcos-Fajardo, M, Sadaka, C, Leroy, V, Benhamou, M, Novak, J, Vrtovsniak, F, Haddad, E, Chintalacheruvu, KR, Monteiro, RC: Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. *J Am Soc Nephrol*, 15: 622-634, 2004.
23. Kiryluk, K, Moldoveanu, Z, Sanders, JT, Eison, TM, Suzuki, H, Julian, BA, Novak, J, Gharavi, AG, Wyatt, RJ: Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schonlein purpura nephritis. *Kidney Int*, 80: 79-87, 2011.
24. Lomax-Browne, HJ, Visconti, A, Pusey, CD, Cook, HT, Spector, TD, Pickering, MC, Falchi, M: IgA1 Glycosylation Is Heritable in Healthy Twins. *J Am Soc Nephrol*, 2016.
25. Hastings, MC, Moldoveanu, Z, Julian, BA, Novak, J, Sanders, JT, McGlothlan, KR, Gharavi, AG, Wyatt, RJ: Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability. *Clin J Am Soc Nephrol*, 5: 2069-2074, 2010.
26. Gharavi, AG, Moldoveanu, Z, Wyatt, RJ, Barker, CV, Woodford, SY, Lifton, RP, Mestecky, J, Novak, J, Julian, BA: Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. *J Am Soc Nephrol*, 19: 1008-1014, 2008.
27. Altshuler, DM, Gibbs, RA, Peltonen, L, Dermitzakis, E, Schaffner, SF, Yu, F, Bonnen, PE, de Bakker, PI, Deloukas, P, Gabriel, SB, Gwilliam, R, Hunt, S, Inouye, M, Jia, X, Palotie, A, Parkin, M, Whittaker, P, Chang, K, Hawes, A, Lewis, LR, Ren, Y, Wheeler, D, Muzny, DM, Barnes, C, Darvishi, K, Hurler, M, Korn, JM, Kristiansson, K, Lee, C, McCarroll, SA, Nemesh, J, Keinan, A, Montgomery, SB, Pollack, S, Price, AL, Soranzo, N, Gonzaga-Jauregui, C, Anttila, V, Brodeur, W, Daly, MJ, Leslie, S, McVean, G, Moutsianas, L, Nguyen, H, Zhang, Q, Ghorji, MJ, McGinnis, R, McLaren, W, Takeuchi, F, Grossman, SR, Shlyakhter, I, Hostetter, EB, Sabeti, PC, Adebamowo, CA, Foster, MW, Gordon, DR, Licinio, J, Manca, MC, Marshall, PA, Matsuda, I,

- Ngare, D, Wang, VO, Reddy, D, Rotimi, CN, Royal, CD, Sharp, RR, Zeng, C, Brooks, LD, McEwen, JE: Integrating common and rare genetic variation in diverse human populations. *Nature*, 467: 52-58, 2010.
28. Ju, T, Cummings, RD: A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. *Proc Natl Acad Sci U S A*, 99: 16613-16618, 2002.
  29. Alexander, WS, Viney, EM, Zhang, JG, Metcalf, D, Kauppi, M, Hyland, CD, Carpinelli, MR, Stevenson, W, Croker, BA, Hilton, AA, Ellis, S, Selan, C, Nandurkar, HH, Goodnow, CC, Kile, BT, Nicola, NA, Roberts, AW, Hilton, DJ: Thrombocytopenia and kidney disease in mice with a mutation in the C1galt1 gene. *Proc Natl Acad Sci U S A*, 103: 16442-16447, 2006.
  30. Smith, AC, de Wolff, JF, Molyneux, K, Feehally, J, Barratt, J: O-glycosylation of serum IgD in IgA nephropathy. *J Am Soc Nephrol*, 17: 1192-1199, 2006.
  31. Yu, CH, Pal, LR, Moulton, J: Consensus Genome-Wide Expression Quantitative Trait Loci and Their Relationship with Human Complex Trait Disease. *Omics : a journal of integrative biology*, 20: 400-414, 2016.
  32. Gerstein, MB, Kundaje, A, Hariharan, M, Landt, SG, Yan, KK, Cheng, C, Mu, XJ, Khurana, E, Rozowsky, J, Alexander, R, Min, R, Alves, P, Abyzov, A, Addleman, N, Bhardwaj, N, Boyle, AP, Cayting, P, Charos, A, Chen, DZ, Cheng, Y, Clarke, D, Eastman, C, Euskirchen, G, Fietze, S, Fu, Y, Gertz, J, Grubert, F, Harman, A, Jain, P, Kasowski, M, Lacroute, P, Leng, J, Lian, J, Monahan, H, O'Geen, H, Ouyang, Z, Partridge, EC, Patacsil, D, Pauli, F, Raha, D, Ramirez, L, Reddy, TE, Reed, B, Shi, M, Slifer, T, Wang, J, Wu, L, Yang, X, Yip, KY, Zilberman-Schapira, G, Batzoglou, S, Sidow, A, Farnham, PJ, Myers, RM, Weissman, SM, Snyder, M: Architecture of the human regulatory network derived from ENCODE data. *Nature*, 489: 91-100, 2012.
  33. Wang, J, Zhuang, J, Iyer, S, Lin, X, Whitfield, TW, Greven, MC, Pierce, BG, Dong, X, Kundaje, A, Cheng, Y, Rando, OJ, Birney, E, Myers, RM, Noble, WS, Snyder, M, Weng, Z: Sequence features and chromatin structure around the genomic regions bound by 119 human transcription factors. *Genome research*, 22: 1798-1812, 2012.
  34. Watanabe, K, Sugai, M, Nambu, Y, Osato, M, Hayashi, T, Kawaguchi, M, Komori, T, Ito, Y, Shimizu, A: Requirement for Runx proteins in IgA class switching acting downstream of TGF-beta 1 and retinoic acid signaling. *J Immunol*, 184: 2785-2792, 2010.
  35. Zeng, J, Mi, R, Wang, Y, Li, Y, Lin, L, Yao, B, Song, L, van Die, I, Chapman, AB, Cummings, RD, Jin, P, Ju, T: Promoters of Human Cosmc and T-synthase Genes Are Similar in Structure, Yet Different in Epigenetic Regulation. *The Journal of biological chemistry*, 290: 19018-19033, 2015.
  36. Yamada, K, Kobayashi, N, Ikeda, T, Suzuki, Y, Tsuge, T, Horikoshi, S, Emancipator, SN, Tomino, Y: Down-regulation of core 1 beta1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. *Nephrol Dial Transplant*, 25: 3890-3897, 2010.
  37. Suzuki, H, Raska, M, Yamada, K, Moldoveanu, Z, Julian, BA, Wyatt, RJ, Tomino, Y, Gharavi, AG, Novak, J: Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes. *The Journal of biological chemistry*, 289: 5330-5339, 2014.
  38. Smith, AC, Molyneux, K, Feehally, J, Barratt, J: O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy. *J Am Soc Nephrol*, 17: 3520-3528, 2006.
  39. Li, GS, Zhang, H, Lv, JC, Shen, Y, Wang, HY: Variants of C1GALT1 gene are associated with the genetic susceptibility to IgA nephropathy. *Kidney Int*, 71: 448-453, 2007.
  40. Zhu, L, Tang, W, Li, G, Lv, J, Ding, J, Yu, L, Zhao, M, Li, Y, Zhang, X, Shen, Y, Zhang, H, Wang, H: Interaction between variants of two glycosyltransferase genes in IgA nephropathy. *Kidney Int*, 76: 190-198, 2009.
  41. Pirulli, D, Crovella, S, Ulivi, S, Zadro, C, Bertok, S, Rendine, S, Scolari, F, Foramitti, M, Ravani, P, Roccatello, D, Savoldi, S, Cerullo, G, Lanzilotta, SG, Bisceglia, L, Zelante, L, Floege, J, Alexopoulos, E, Kirmizis, D, Ghiggeri, GM, Frasca, G, Schena, FP, Amoroso, A: Genetic variant

- of C1GalT1 contributes to the susceptibility to IgA nephropathy. *Journal of nephrology*, 22: 152-159, 2009.
42. An, J, Lu, Q, Zhao, H, Cao, Y, Yan, B, Ma, Z: A study on the association between C1GALT1 polymorphisms and the risk of Henoch-Schonlein purpura in a Chinese population. *Rheumatology international*, 33: 2539-2542, 2013.
  43. He, X, Zhao, P, Kang, S, Ding, Y, Luan, J, Liu, Z, Wu, Y, Yin, W: C1GALT1 polymorphisms are associated with Henoch-Schonlein purpura nephritis. *Pediatr Nephrol*, 27: 1505-1509, 2012.
  44. Brion, MJ, Shakhbazov, K, Visscher, PM: Calculating statistical power in Mendelian randomization studies. *International journal of epidemiology*, 42: 1497-1501, 2013.
  45. Kiryluk, K, Li, Y, Scolari, F, Sanna-Cherchi, S, Choi, M, Verbitsky, M, Fasel, D, Lata, S, Prakash, S, Shapiro, S, Fischman, C, Snyder, HJ, Appel, G, Izzi, C, Viola, BF, Dallera, N, Del Vecchio, L, Barlassina, C, Salvi, E, Bertinetto, FE, Amoroso, A, Savoldi, S, Rocchietti, M, Amore, A, Peruzzi, L, Coppo, R, Salvadori, M, Ravani, P, Magistroni, R, Ghiggeri, GM, Caridi, G, Bodria, M, Lugani, F, Allegri, L, Delsante, M, Maiorana, M, Magnano, A, Frasca, G, Boer, E, Boscutti, G, Ponticelli, C, Mignani, R, Marcantoni, C, Di Landro, D, Santoro, D, Pani, A, Polci, R, Feriozzi, S, Chicca, S, Galliani, M, Gigante, M, Gesualdo, L, Zamboli, P, Battaglia, GG, Garozzo, M, Maixnerova, D, Tesar, V, Eitner, F, Rauen, T, Floege, J, Kovacs, T, Nagy, J, Mucha, K, Paczek, L, Zaniew, M, Mizerska-Wasiak, M, Roszkowska-Blaim, M, Pawlaczyk, K, Gale, D, Barratt, J, Thibaudin, L, Berthoux, F, Canaud, G, Boland, A, Metzger, M, Panzer, U, Suzuki, H, Goto, S, Narita, I, Caliskan, Y, Xie, J, Hou, P, Chen, N, Zhang, H, Wyatt, RJ, Novak, J, Julian, BA, Feehally, J, Stengel, B, Cusi, D, Lifton, RP, Gharavi, AG: Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. *Nat Genet*, 46: 1187-1196, 2014.
  46. Stanescu, HC, Arcos-Burgos, M, Medlar, A, Bockenhauer, D, Kottgen, A, Dragomirescu, L, Voinescu, C, Patel, N, Pearce, K, Hubank, M, Stephens, HA, Laundry, V, Padmanabhan, S, Zawadzka, A, Hofstra, JM, Coenen, MJ, den Heijer, M, Kiemeneij, LA, Bacq-Daian, D, Stengel, B, Powis, SH, Brenchley, P, Feehally, J, Rees, AJ, Debiec, H, Wetzels, JF, Ronco, P, Mathieson, PW, Kleta, R: Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. *N Engl J Med*, 364: 616-626, 2011.
  47. Tobin, MD, Raleigh, SM, Newhouse, S, Braund, P, Bodycote, C, Ogleby, J, Cross, D, Gracey, J, Hayes, S, Smith, T, Ridge, C, Caulfield, M, Sheehan, NA, Munroe, PB, Burton, PR, Samani, NJ: Association of WNK1 gene polymorphisms and haplotypes with ambulatory blood pressure in the general population. *Circulation*, 112: 3423-3429, 2005.
  48. Barrett, JC, Fry, B, Maller, J, Daly, MJ: Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics*, 21: 263-265, 2005.
  49. Purcell, S, Neale, B, Todd-Brown, K, Thomas, L, Ferreira, MA, Bender, D, Maller, J, Sklar, P, de Bakker, PI, Daly, MJ, Sham, PC: PLINK: a tool set for whole-genome association and population-based linkage analyses. *American journal of human genetics*, 81: 559-575, 2007.
  50. Purcell, S: PLINK v1.9. 2015.
  51. Fuchsberger, C, Abecasis, GR, Das, S: University of Michigan Imputation Server. 2016.
  52. Allen, AC, Harper, SJ, Feehally, J: Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. *Clin Exp Immunol*, 100: 470-474, 1995.

## Figure Legends

**Figure 1.** Gd-IgA1 levels were higher in 379 patients with IgAN compared with 638 healthy control subjects ( $p < 0.0001$ ). Levels were higher in 154 patients with progressive IgAN (defined as doubling of serum creatinine or ESKD) compared 123 IgAN patients in whom good renal function remained stable over  $>5$  years ( $p = 0.0011$ ). Gd-IgA1 levels were not significantly elevated in 308 patients with membranous nephropathy (MN controls). AU, arbitrary units of optical absorbance.

**Figure 2.** Heritability ( $h^2$ ) of Gd-IgA1 in UK Caucasians is 0.387. This was estimated using 134 complete trios by plotting Gd-IgA1 of patients against their mean parental Gd-IgA1. Values plotted are Gd-IgA1 levels in arbitrary units of optical absorbance standardized to mean of 0 and standard deviation of 1 to allow narrow sense heritability estimation by calculation of the slope.

**Figure 3.** Genome wide association study of Gd-IgA1 levels in 513 unrelated UK individuals. Manhattan plot (left panel) showing significance of the association of each SNP allele with Gd-IgA1 level by plotting the negative logarithm to the base 10 of the P value against the genomic position. Horizontal line indicates conventional genome-wide significance ( $p=5 \times 10^{-8}$ ). Quantile-quantile plot (right panel) is a plot of the observed  $-\log_{10}(p)$  against the  $-\log_{10}(p)$  values that would be expected under the null hypothesis of no association. Deviation above the  $y=x$  line indicates lower p values than would be expected to occur by chance and implies statistically significant association. The genomic inflation factor was 1.00196.

**Figure 4.** Gd-IgA1 levels were elevated in 704 Han Chinese patients with IgAN compared with 111 healthy Chinese subjects ( $p = 0.015$ ). Levels in both Chinese groups were significantly lower than those in UK healthy subjects and UK patients with IgAN ( $p < 0.0001$  for both). 10% of Chinese and 24% of UK subjects with IgAN exhibited Gd-IgA1 levels above the 95<sup>th</sup> percentile of their respective control populations. AU, arbitrary units of optical absorbance.

**Figure 5.** Gd-IgA1 levels increase with copies of the H1 haplotype in Chinese and Caucasian populations. In the combined IgA and MN (Caucasian) cohort (left panel) haplotype frequency was 0.32 (N = 821,  $R^2 = 0.033$ ,  $p < 0.0001$ ). In Chinese IgAN patients (right panel) haplotype frequency was 0.04 (N = 704,  $R^2 = 0.019$ ,  $p < 0.001$ ). In multiple regression analysis, Chinese ethnicity was associated with lower Gd-IgA1 levels than in Caucasians, even correcting for haplotype frequency and disease status ( $p < 0.0001$ ). AU, arbitrary units of optical absorbance.

| Chromosome | SNP         | Raw P value | GC       | Bonferroni | GRAPHIC P |
|------------|-------------|-------------|----------|------------|-----------|
| 7          | *rs1008897  | 2.35E-09    | 2.55E-09 | 0.000745   | 5.49E-11  |
| 7          | *rs758263   | 4.34E-09    | 4.70E-09 | 0.001377   | 1.90E-07  |
| 7          | *rs13226913 | 6.55E-09    | 7.07E-09 | 0.002077   | 1.19E-08  |
| 7          | *rs4720724  | 3.91E-07    | 4.14E-07 | 0.1238     | 7.51E-09  |
| 17         | rs3803780   | 4.06E-06    | 4.26E-06 | 1          | 0.982     |
| 8          | rs1344616   | 4.62E-06    | 4.85E-06 | 1          | 0.510     |
| 6          | rs9383456   | 6.48E-06    | 6.80E-06 | 1          | 0.755     |
| 11         | rs519380    | 6.79E-06    | 7.12E-06 | 1          | 0.598     |
| 11         | rs2279865   | 7.52E-06    | 7.88E-06 | 1          | 0.0545    |
| 2          | rs294657    | 7.89E-06    | 8.27E-06 | 1          | 0.807     |
| 11         | rs11550299  | 1.03E-05    | 1.08E-05 | 1          | 0.427     |
| 13         | rs1540510   | 1.13E-05    | 1.19E-05 | 1          | 0.621     |
| 7          | *rs2108780  | 1.46E-05    | 1.53E-05 | 1          | 3.10E-06  |
| 7          | rs2060163   | 1.59E-05    | 1.66E-05 | 1          | 0.00115   |
| 8          | rs609760    | 1.73E-05    | 1.80E-05 | 1          | 0.605     |
| 1          | rs12140760  | 1.82E-05    | 1.90E-05 | 1          | 0.0227    |

**Table 1.** All SNPs associated with Gd-IgA1 with  $p < 5 \times 10^{-5}$  in discovery cohort. \*SNPs at the *C1GALT1* locus – only these SNPs also showed significant association with Gd-IgA1 in the GRAPHIC cohort. GC, corrected for Genomic Control; Bonferroni, corrected stringently for 302,210 SNPs analysed.

| Cohort    | CHR     | SNP1      | SNP2      | HAPLOTYPE     | Frequency     | Beta         | P               | Bonferroni      |
|-----------|---------|-----------|-----------|---------------|---------------|--------------|-----------------|-----------------|
| Caucasian | 7       | rs4720724 | rs2190935 | <b>GTCCGC</b> | <b>0.319</b>  | <b>0.343</b> | <b>4.40E-11</b> | <b>3.96E-10</b> |
|           | 7       | rs4720724 | rs2190935 | ATCTAT        | 0.207         | 0.0498       | 0.397           | 1               |
|           | 7       | rs4720724 | rs2190935 | AGCTAC        | 0.17          | -0.315       | 1.36E-06        | 1.22E-05        |
|           | 7       | rs4720724 | rs2190935 | AGTCAT        | 0.134         | -0.237       | 0.00153         | 0.0138          |
|           | 7       | rs4720724 | rs2190935 | GGTCAT        | 0.0479        | -0.19        | 0.118           | 1               |
|           | 7       | rs4720724 | rs2190935 | AGTTAC        | 0.0429        | -0.258       | 0.0421          | 0.379           |
|           | 7       | rs4720724 | rs2190935 | ATCCGC        | 0.0154        | 0.058        | 0.78            | 1               |
|           | 7       | rs4720724 | rs2190935 | GTCTAT        | 0.012         | 0.304        | 0.214           | 1               |
|           | 7       | rs4720724 | rs2190935 | GTCCAC        | 0.0113        | 0.248        | 0.265           | 1               |
|           | 7       | rs4720724 | rs2190935 | AGCTAC        | 0.523         | -0.184       | 0.000592        | 0.00538         |
|           | 7       | rs4720724 | rs2190935 | AGTCAT        | 0.162         | 0.0761       | 0.307           | 1               |
|           | 7       | rs4720724 | rs2190935 | AGTTAC        | 0.162         | 0.18         | 0.0165          | 0.149           |
|           | 7       | rs4720724 | rs2190935 | <b>GTCCGC</b> | <b>0.0359</b> | <b>0.536</b> | <b>6.21E-05</b> | <b>5.59E-04</b> |
|           | Chinese | 7         | rs4720724 | rs2190935     | GGTCAT        | 0.0211       | 0.0119          | 0.949           |
| 7         |         | rs4720724 | rs2190935 | ATTCAT        | 0.0195        | -0.0189      | 0.928           | 1               |
| 7         |         | rs4720724 | rs2190935 | GTTCGC        | 0.0142        | -0.392       | 0.102           | 0.918           |
| 7         |         | rs4720724 | rs2190935 | ATCCGC        | 0.0107        | -0.148       | 0.542           | 1               |
| 7         |         | rs4720724 | rs2190935 | AGCTAC        | 0.01          | 0.224        | 0.431           | 1               |

**Table 2.** Association of haplotypes across *C1GALT1* with Gd-IgA1 showing a similar effect of the H1 haplotype (bold) in both populations. P values represent the effect of testing each haploptype against all of the others. The commonest haplotype in the UK population is almost 10-fold less common in the Chinese population. SNPs defining this haplotype are rs4720724, rs758263, rs4263662, rs10259085, rs1008897, rs2190935. Bonferroni, with correction for 9 haplotypes tested.

| SNP               | Position       | Gd-IgA1 P-value<br>(imputed) | GRAPHIC<br>Replication P | Cell type  | eQTL P-Value      |
|-------------------|----------------|------------------------------|--------------------------|------------|-------------------|
| rs10246303        | 7286445        | 6.488E-10                    | 3.906E-08                | LCL        | 3.03884E-09       |
| rs6463656         | 7244181        | 7.576E-09                    | 1.458E-08                | LCL        | 3.00367E-08       |
| rs6463657         | 7244254        | 7.576E-09                    | 1.455E-08                | LCL        | 3.40312E-08       |
| <b>rs13226913</b> | <b>7246846</b> | <b>7.576E-09</b>             | <b>1.19E-08</b>          | <b>LCL</b> | <b>3.8322E-08</b> |
| rs10251505        | 7254489        | 1.561E-08                    | 1.721E-08                | LCL        | 2.03717E-08       |
| rs4318980         | 7256490        | 1.767E-08                    | 1.426E-08                | LCL        | 1.44846E-08       |
| rs7780273         | 7250449        | 1.883E-08                    | 0.00010165               | LCL        | 3.11303E-09       |
| rs2881755         | 7256439        | 2.022E-08                    | 1.544E-07                | LCL        | 1.07186E-07       |
| rs2881756         | 7256439        | 2.022E-08                    | N/A                      | LCL        | 1.46728E-07       |
| rs10952047        | 7289543        | 2.358E-08                    | 2.003E-06                | LCL        | 1.7149E-11        |
| rs4720726         | 7225451        | 3.287E-08                    | 1.68E-04                 | LCL        | 7.5698E-09        |
| rs11771259        | 7277215        | 3.691E-08                    | 5.363E-06                | LCL        | 1.14591E-11       |
| rs4724958         | 7226553        | 7.369E-08                    | 0.00017043               | LCL        | 9.72937E-09       |
| rs4720727         | 7226695        | 1.704E-07                    | 2.569E-07                | LCL        | 6.11804E-08       |
| rs12702588        | 7222806        | 3.597E-07                    | N/A                      | LCL        | 7.84334E-07       |
| rs57552003        | 7223104        | 6.837E-07                    | 5.952E-06                | LCL        | 5.51448E-08       |
| rs11773545        | 7196878        | 8.911E-07                    | 0.00176318               | LCL        | 1.59081E-06       |
| rs1047763         | 7283569        | 1.034E-06                    | 2.018E-06                | LCL        | 3.64039E-11       |

**Table 3.** Expression quantitative trait loci (eQTLs) of SNPs associated with Gd-IgA1<sup>31</sup>. Gd-IgA1 p-values are imputed, except for rs13226913 which was directly genotyped. All these SNPs are on the H1 haplotype and the allele associated with elevated Gd-IgA1 levels is associated with lower transcript levels in all cases. LCL, Lymphoblastoid Cell Line.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5